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Editorrial

Direct-to-Consumer Advertising
For Erectile Dysfunction Drugs
i n c reased patient knowledge
ou’ve seen the commerand motivation for self-care, as
cials on television: the
well as improved health-seeking
guy band singing a wellbehaviors
that empower indiknown Elvis Presley tune
viduals to consult their care
but with different lyrics; the fiftyprovider about problems they
something couple dancing with
have
been hesitant to discuss.
wanting looks in their eyes; the
The
downside
of DTCA is the
couple in his and her clawfoot
increased risk of inappropriate
bathtubs on the beach. These are all
or excessive prescriptions, highimages that are part of the direct-toer
prescription costs to individuconsumer advertising (DTCA)
als
and insurers, as well as the
effort by pharmaceutical compainappropriate or over diagnosis
nies that manufacture medications
of certain health conditions.
for erectile dysfunction (ED).
M
oreover, many believe DTCA
ED is a significant clinical
contributes
to consumer misinhealth problem that urologic care
formation, thus putting health
professionals discuss with ease.
care providers in the awkward
However, many in the general
Karen A. Karlowicz, EdD, MSN, RN
and
time-consuming position of
public find open talk of sexual
convincing
patients that the
health problems an invasion of
drug they are requesting is not in their best interest
privacy, embarrassing, inappropriate, or even taboo.
(Montoya, Lee-Dukes, & Shaw, 2008).
The level of discomfort that many have regarding this
My concern regarding DTCA for ED drugs is the
topic is escalating with the increasing number of comlack
of objective evidence that documents the benefits
mercials promoting ED drugs, especially during primeor limitations of this marketing approach. The dearth
time television viewing. In fact, as I write this editoriof research on this topic, as well as for those drugs
al, I have seen no less than four advertisements for ED
widely
marketed for overactive bladder, represents
drugs in the hour between 10:00 to 11:00 p.m. on CNN.
t
remendous
research opportunities for urology nurses.
Frustrated and outraged by the ads for ED drugs
As for H.R. 2175, I understand the motivation for
on television, on April 29, 2009, Rep. James P. Moran
the legislation introduced (I still don’t get what a cou(VA) introduced H.R. 2175, Families for ED
ple
in separate bathtubs on the beach has to do with
A d v e rtising Decency Act. This bill is intended to prosex
or ED!), but I wonder whether a legislative
hibit the broadcasting of any advertisement for medapproach is appropriate or needed to address the conication for the treatment of ED or other purposes. It
cerns regarding DTCA for ED drugs. Urologic nurses
has been referred to the House Committee on Energy
have
a long history of partnering with the pharmaceuand Commerce for further consideration.
tical
industry to provide education to professionals
DTCA has been on the rise world-wide over the
and patients. Thus, it seems to me that the time has
past 15 years, due in part to government efforts to
come for us to engage our pharmaceutical partners in a
reduce the influence of the pharmaceutical industry on
serious
discussion on how to best provide education
those with prescriptive authority. With less advertising
about
ED
drugs in a way that is responsible, meets the
dollars dedicated to activities for health care providers,
needs of all stakeholders, and yet, is not offensive to
p h a rmaceutical companies have re d i rected their
the public.
advertising budgets for patent-protected, brand name
drugs to consumer marketing. In 2006, about 40% of
K a ren A. Karlowicz, EdD, MSN, RN
all advertising dollars, totaling an estimated $4.8 bilEditorial Board Member
lion, was spent on DTCA by drug companies. In the
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